Circulating tumor cells in Waldenström macroglobulinemia
Clémentine Boccon-Gibod,Elise Sourdeau,Pierre Morel,Elise Chapiro,Florence Nguyen-Khac,Clotilde Bravetti,Frédéric Davi,Véronique Morel,Nicolas Gauthier,Adrien Grenier,Inès Boussen,Sylvain Choquet,Véronique Leblond,Magali Le Garff-Tavernier,Marine Baron,Damien Roos-Weil
DOI: https://doi.org/10.1038/s41375-024-02156-3
2024-02-09
Leukemia
Abstract:Waldenström macroglobulinemia (WM) is a rare mature B-cell neoplasm defined by the association of a serum monoclonal IgM gammopathy and bone marrow (BM) infiltration by lymphoplasmocytic lymphoma [1]. Differential diagnosis with other indolent B-cell lymphomas, including marginal zone lymphoma (MZL), is sometimes difficult, due to overlapping clinico-biological features. Indeed, detection of a monoclonal IgM component is common in MZL, and the MYD88 L265P mutation, a hallmark of WM, can also be detected in a proportion of MZL cases [2, 3], whereas splenomegaly and lymphocytosis, though more commonly associated with MZL, is sometimes observed in WM. Although WM patients with cytologically detectable circulating lymphoplasmocytes have been described, the exact proportion of WM patients who present with circulating tumor cells (CTCs) and the potential correlation with clinico-biological characteristics is not known. Molecular features may influence the presence and level of CTCs, notably CXCR4 mutations that have been shown to increase medullar homing of CXCR4 -mutated B-cells [4, 5]. This could be also relevant for prognosis, since the detection of CTCs in other lymphoid neoplasms (such as follicular lymphoma or myeloma) has been recently shown to confer a poorer prognosis [6, 7]. We therefore aimed in a large cohort of WM patients to evaluate the presence of detectable CTCs by flow cytometry (FCM) at diagnosis, their potential correlation with clinico-biological features and outcomes.
oncology,hematology